Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AVTX
AVTX | US
13.92
USD-0.83
-5.63%
AVTX | US
Loading StockChartView...
About AVTX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
13.92
Open
14.75
High
15.11
Low
13.73
Avalo Therapeutics Inc. a clinical stage biotechnology company focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002 a fully human anti-LIGHT monoclonal antibody which is under Phase II clinical trial for the treatment of non-eosinophilic asthma as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008 a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803 a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics Inc. in August 2021. Avalo Therapeutics Inc. was incorporated in 2011 and is headquartered in Rockville Maryland.
View LessAVTX | US
Risk
83.1
Sharpe
2.13
Luna's Score
43/100
Recommendation
Sell
Luna says (AVTX | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
64.2%1 month
83.1%3 months
75.9%6 months
72.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.66
Debt to equity
-0.80
Debt to assets
0.02
Ent. to EBITDA
-0.19
Ent. to rev.
19.29
PEG
-
Other Fundamentals
EBITDA
-22.05M
MarketCap
135.02M
MarketCap(USD)
135.02M
Div. yield
-
Op. margin
-2.75K
Erngs. growth
-
Rev. growth
-36.30
Ret. on equity
-524.01
Short ratio
3.46
Short perc.
0.56
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.12
Range1M
5.32
Range3M
6.04
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.92
Price X volume
10.33M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.19 | 0.53 | Cheaper |
| Ent. to Revenue | 19.29 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.66 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 75.86 | 72.80 | Par |
| Debt to Equity | -0.80 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 135.02M | 3.66B | Emerging |
